GSK CEO dismisses rumors of AstraZeneca takeover

05/21/2008 | Reuters · Wall Street Journal (free content), The

Buying AstraZeneca could cause antitrust problems and does not fit GlaxoSmithKline's acquisition strategy, outgoing CEO Jean-Pierre Garnier said at a meeting Wednesday. Such a deal also would weaken research and development productivity because GSK has a stronger pipeline of new drugs than AstraZeneca, Garnier said. A spokesman for AstraZeneca said the company is expected to deliver an average of two treatments per year to market from 2010 onward.

View Full Article in:

Reuters · Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC